Fig. 9

a–l Outcomes (for RFi and OS) of GEX signatures. Kaplan–Meier plots representing the relationship between RFi or OS and GEX levels in terms of quartiles (Q1–Q4) for the whole cohort (n = 437) for a–b BC proliferation, c–d ESR1, e–f FOXA1, g–h hypoxia, i–j Mast cells, and k–l PGR. HRs with 95% CI are shown for the full-time follow-up and the first 10 years. CI confidence interval, ER estrogen receptor, GEX gene expression, HER2 human epidermal growth factor receptor 2, HR hazard ratio, OS overall survival, Q quartile, RFi recurrence-free interval, Tam tamoxifen